Home Health VNA
IV Medication Clinical Fact Sheet

IV Medication: Dalbavancin/Dalvance Risk Level: n/a

Med Class: Antibiotics

Note: All antibiotics carry risk of hypersensitivity reaction at any time during the course of treatment

Superinfections are possible with all antibiotics

Common Uses: Acute bacterial skin and skin structure infections by susceptible strains of Gram-positive microorganisms including Staphylococcus aureus and methicillin-resistant S. aureus (MRSA)

Labs to Monitor: C-reactive protein (CRP), CBC with Differential, comprehensive metabolic panel, sedimentation rate, automated ESR.

Instructions:
- IV infused over 30 mins.
- If a common IV line is used; flush before and after infusion with D5W.
- Can be reconstituted using sterile water or 5% dextrose solution to a final concentration of 1mg/mL to 5mg/mL.

Precautions:
- If given too quickly may cause "red man syndrome" – upper body flushing, pruritis, back pain, urticaria, rash. Slow infusion if symptoms occur.
- Vancomycin sensitivity – glycopeptide antibiotics are structurally similar to Vancomycin.
- Known hypersensitivity to glycopeptides.
- Dosage may vary in patients with renal impairment
- Total time of reconstitution should not exceed 48 hours.
- Liver disease/kidney disease

Common Side Effects: Common side effects including nausea (4.7%), headache (3.8%), C-Diff associated diarrhea (3.4%), flushing (<2%), phlebitis (<2%), pruritis (2%), skin rash (3%), urticaria (<2%), hypoglycemia (<2%),

Contraindications:
- Do not co-infuse with other medications or electrolytes.
- Do not reconstitue using saline-based products.

First Dose Allowed:	Y
Central Line Only:	N
IV Push:	N
Vesicant:	N

See Procedure Manual: Intravenous Infusions

Resource(s):

- FDA. (July 2018). Dalvance. Prescribing Information. Reference ID: 4296015. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021883s007lbl.pdf
- Mayo Clinic. (February 1, 2024). Dalbavancin (Intravenous Route). Retrieved from https://www.mayoclinic.org/drugs-supplements/dalbavancin-intravenous-route/side-effects/drg-20110160?p=1
- Medscape.com. (n.d.). dalavancin (Rx). Retrieved on 2/26/24 from https://reference.medscape.com/drug/dalvance-dalbavancin-999921
- UptoDate. Dalbavancin. Retrieved on 3/26/2024 from https://www.uptodate.com/contents/search?search=dalbavancin&sp=1&searchType=PLAIN_TEXT&source=USER_PREF&searchControl=TOP_PULLDOWN&autoComplete=false

Notes: Only drugs listed as First Dose Allowed may be given in the home as a first dose and are considered for a first dose on a case by case basis by the IV Program Manager

The IV Manager and/or Clinical Director must be consulted before a first dose referral is accepted

Risk Levels:	n/a =	Routinely given; Clinician must be approved to administer IV medications
	1=	IV Program Mgr or Clinical Director approval before referral is accepted
	2=	IV Program Mgr notification; Clinicians must review Special Instructions
Approved	3/27/2024	